ASN002 demonstrates efficacy and improves inflammation in AD

Summary Few medicines are available for the treatment of moderate‐to‐severe atopic eczema. ASN002 is a new oral (taken by mouth) drug being tested that has been shown to reduce the activity of various proteins playing a role in skin inflammation. In the present study, the safety and efficacy of diff...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	British journal of dermatology (1951) 2019-10, Vol.181 (4), p.e102-e102
Hauptverfasser:	Bissonnette, R., Maari, C., Forman, S., Bhatia, N., Lee, M., Fowler, J., Tyring, S., Pariser, D., Sofen, H., Dhawan, S., Zook, M., Zammit, D.J., Usansky, H., Denis, L., Rao, N., Song, T., Pavel, A.B., Guttman‐Yassky, E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Atopy Eczema Inflammation Side effects Skin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!